Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/74—Rubiaceae (Madder family)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
  • A61K36/18—Magnoliophyta (angiosperms)
  • A61K36/185—Magnoliopsida (dicotyledons)
  • A61K36/75—Rutaceae (Rue family)
  • A61K36/752—Citrus, e.g. lime, orange or lemon
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
  • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
  • A61K8/9783—Angiosperms [Magnoliophyta]
  • A61K8/9789—Magnoliopsida [dicotyledons]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Definitions

• the present invention relates to new uses of hesperetin, in particular for cosmetic use, and more particularly to the action of hesperetin as a chemical component for improving skin microcirculation, particularly in the treatment of black eyelids in the eye. use. Background technique
• the structure of the human eye's skin is different from other parts of the human skin.
• Hesperetin is a dihydroflavonoid derived from the peel or fruit of the genus Citrus in the genus Rutaceae. Its structural formula is as follows:
• the molecular weight is 610.57, which is pale yellow needle crystal at normal temperature.
• hesperetin has many important biological and pharmacodynamic activities, including anti-oxidation, anti-inflammatory, hypolipidemic, cardiovascular and anti-cancer effects, but The use of hesperetin to improve skin microcirculation has not been reported. It is still desired by those skilled in the art to develop new products having an effect of improving skin microcirculation, particularly those having an effect of improving microcirculation of the ocular skin. Summary of the invention
• the present inventors have surprisingly found that the use of hesperetin or a plant extract comprising hesperetin can effectively improve skin microcirculation, in particular to improve eye microcirculation, and more particularly Effectively remove dark eyelids.
• the present invention has been completed based on the above findings.
• the first aspect of the present invention provides hesperetin or a plant extract comprising hesperetin for preparing a condition for improving and/or promoting skin microcirculation, or eliminating and/or alleviating a condition associated with poor skin microcirculation or The use of the state of the product.
• the skin microcirculation is an ocular skin microcirculation.
• condition or condition associated with poor microcirculation of the skin refers to a condition or condition associated with poor microcirculation of the ocular surface of the eye.
• condition or state associated with poor microcirculation of the ocular skin refers to black eyelids.
• the plant extract containing hesperetin is obtained from the peel and/or fruit of the citrus plant of the genus Rutaceae or the aerial part of the genus Chrysosporium Extract.
• the plant extract containing hesperetin is obtained from the peel and/or fruit of the citrus plant of the genus Rutaceae or the aerial part of the genus Chrysosporium
• the extract, and the hesperetin content in the extract is not less than 50% by weight.
• the hesperetin content in the extract is 60% by weight or more, 70% by weight or more, 80% by weight or more, 85% by weight or more, 90% by weight or more, or 95% by weight or more.
• the product is a locally applied product for external use on the skin.
• the product is a product for topical application to the ocular skin.
• the product is a cosmetic.
• the product is in the form of a solution, a milk, a paste, a cream, or a gel.
• the product comprises: (1) hesperetin or a plant extract comprising hesperetin, and (2) a physiologically acceptable excipient.
• the product comprises: (1) hesperetin or a plant extract comprising hesperetin, and (2) a physiologically acceptable excipient; and wherein the orange peel 01-20 ⁇
• the percentage of the total weight of the product is 0.10-20% by weight. In one embodiment. 1-10 ⁇ %, 0. 2-10 ⁇ %, the percentage of the total weight of the product of the hesperetin or hesperetin is 0. 05-15% by weight, 0. 1-10% by weight, 0. 2-10% by weight , or 0. 2-5 wt%.
• a second aspect of the invention provides a composition comprising: (1) an effective amount of hesperetin or a plant extract comprising hesperetin, and optionally (2) a physiologically acceptable excipient.
• a composition according to the second aspect of the invention comprising: (1) an effective amount of hesperetin or a plant extract comprising hesperetin, and optionally (2) a physiologically acceptable excipient; 01-20 ⁇
• the hesperetin or the plant extract containing hesperetin as a percentage of the total weight of the composition is determined by hesperetin 0. 05-15% by weight, 0. 1-10% by weight, 0. 2-10 weight %, or 0. 2-5 wt%.
• composition according to the second aspect of the present invention wherein the plant extract containing hesperetin is obtained by extracting from the peel and/or fruit of the citrus plant of the genus Rutaceae or the aerial part of the genus Rubiaceae Extract.
• composition according to the second aspect of the present invention wherein the plant extract containing hesperetin is derived from the peel and/or fruit of the genus Citrus in the genus Rutaceae or the Rubiaceae
• the obtained extract is extracted from the aerial part of the plant chestnut piglet, and the hesperetin content in the extract is not less than 50% by weight.
• the hesperetin content in the extract is 60% by weight or more, 70% by weight or more, 80% by weight or more, 85% by weight or more, 90% by weight or more, or 95% by weight or more.
• the skin microcirculation is an ocular skin microcirculation.
• the condition or condition associated with poor skin microcirculation refers to a condition or condition associated with poor microcirculation of the ocular surface of the eye.
• the condition or condition associated with poor microcirculation of the ocular surface of the eye refers to dark eyelids.
• composition according to the second aspect of the invention which is a product for topical application.
• the composition according to the second aspect of the present invention which is a product for topical application for external application to the skin.
• composition according to the second aspect of the invention which is a product for topical application to the skin of the eye.
• composition according to the second aspect of the invention which is a cosmetic.
• a composition according to the second aspect of the invention which is in the form of a solution, a milk, a paste, a cream, or a gel.
• a third aspect of the invention provides a method of ameliorating and/or promoting skin microcirculation in an individual in need thereof, or eliminating and/or alleviating a condition or condition associated with poor microcirculation of the skin, the method comprising administering to the individual an effective amount of Hesperetin or a plant extract containing hesperetin.
• condition or state associated with poor skin microcirculation refers to a condition or state associated with poor microcirculation of the ocular skin.
• condition or state associated with poor microcirculation of the ocular skin refers to black eyelids.
• the plant extract containing hesperetin is obtained by extracting from the peel and/or fruit of the citrus plant of the genus Rutaceae or the aerial part of the genus Rubiaceae Extract.
• the plant extract containing hesperetin is obtained by extracting from the peel and/or fruit of the citrus plant of the genus Rutaceae or the aerial part of the genus Rubiaceae
• the extract, and the hesperetin content in the extract is not less than 50% by weight.
• the hesperetin content in the extract is 60% by weight or more, 70% by weight or more, 80% by weight or more, 85% by weight or more, 90% by weight or more, or 95% by weight or more.
• skin microcirculation refers to the microvascular network under the dermis of the skin, which is the terminal part of the circulation, which belongs to the capillaries, is the junction of arteries and veins, and is the place where the blood and tissue cells exchange material. .
• Skin microcirculation is a complex dynamic system that plays a very important role in skin color, temperature regulation, skin metabolism and transdermal transport, directly affecting skin health.
• disease or condition associated with poor microcirculation of the skin refers to a pathological or non-pathological physical condition or abnormality that occurs due to poor microcirculation or disorder of the skin, such as dermatitis, pigmentation. Calming, skin aging, pale skin, red blood, local skin bloated, local hoarding, black eyelids, etc.
• Disease or condition means that a pathological or non-pathological state of the body or an abnormal condition occurs due to poor microcirculation or disorder of the skin, such as improving local microcirculation of the skin, promoting local microcirculation of the skin, and eliminating skin due to skin A pathological or non-pathological physical state or abnormal condition occurs due to local microcirculation failure or disorder, and a pathological or non-pathological physical state or abnormal condition due to local microcirculation or disorder of the skin is alleviated.
• physiologically acceptable means physiologically compatible, particularly when used in contact with the skin for use in external skin products, for example, without causing side effects such as irritation to the skin.
• a diluent, a surfactant, a thickener, an emollient, or the like which can be used in cosmetics.
• the term "effective amount” refers to a dose that can achieve a treatment, prevention, alleviation, and/or alleviation of a disease or condition described herein in a subject.
• composition which may also refer to "cosmetic”, “cosmetic composition”, “pharmaceutical composition”, which can be used to achieve treatment, prevention, alleviation and/or alleviation in an individual.
• composition which may also refer to "cosmetic”, “cosmetic composition”, “pharmaceutical composition”, which can be used to achieve treatment, prevention, alleviation and/or alleviation in an individual.
• the invention is a disease, disorder, or physical condition.
• the term "individual” may also mean “subject", "patient” or other skin microcirculation that accepts a composition of the invention to ameliorate and/or promote its appearance, or eliminate and/or An animal, particularly a mammal, such as a human, a dog, a monkey, a cow, a horse, etc., especially a human, which alleviates the condition or condition associated with poor microcirculation of the skin.
• ocular skin microcirculation refers to microcirculation in the skin surrounding the eye.
• the hesperetin can be obtained from the peel or the fruit of the genus Citrus in the genus Rutaceae or the aerial part of the genus Rubiaceae, or can be synthesized or biotransformed according to chemical methods known in the art. Got it.
• the hesperetin may be a monomeric compound or an extract having a hesperetin content of not less than 50%.
• the hesperetin is used in an amount of from 0.01% to 20%, preferably from 0.05% to 15%, most preferably from 0.1% to 10%, based on the amount of the hesperidin monomer compound. In the composition of the invention.
• the invention also includes cosmetic skin care compositions containing hesperetin.
• the present invention relates to a cosmetic skin care composition
• a cosmetic skin care composition comprising: (1) hesperetin present in an amount of from 0.1% to 10% by weight; and (2) a medium acceptable for cosmetic use.
• compositions of the present invention are intended to eliminate eye black eyes Effect.
• compositions and methods of the present invention also include a cosmetically acceptable vehicle as a diluent, dispersing or carrier for the active ingredient in the compositions to facilitate dispersion of the compositions when they are applied to the skin.
• Vehicles other than water include liquid or solid emollients, surfactants, solvents, thickeners.
• the active substance is defined as a substance different from the emollient and the component which only improves the physical properties of the composition.
• the effect of reducing or eliminating dark eyelids in the eye can be achieved by topical application of hesperetin.
• the present invention relates to a new use of hesperetin in cosmetics, in particular, hesperetin, as a chemical component for improving skin microcirculation, is a new use for removing eye black eyelids.
• the hesperetin is present in an amount of from 0.01% to 10% by weight of the composition.
• the present invention has studied the effect of the local application of hesperetin on the surface of the skin, and the results show that the topical application of hesperetin can significantly improve the skin microcirculation, and the inventors applied it.
• hesperetin has been found to have a significant effect of eliminating dark eyelids.
• % means Wt%, that is, weight percentage, unless otherwise specified.
• Microcirculation test method Take a weight of 3. 0-3. 5kg male Japanese white rabbit, after shaving the back, use the marker to delineate 10 points of blood flow in the rabbit hairless area, 5 on the left and right sides Point, draw points to avoid large blood vessels; Before applying the sample, the blood flow base value of each group of rabbits was measured by laser Doppler flowmeter. The left side of each group was coated with a blank solution on the left side and the right side was coated with orange. A solution of dermatan (three groups of animals, the concentration of the solution was 0.5%, 1./», 2%, 0.11 liter per animal), and 3 rabbits in parallel for each concentration sample. A 2% solution was administered orally in a similar manner, and the dose was 100 times that of the 2% solution.
• the blood flow values of the same site were measured by laser Doppler flowmeter every hour after administration, and the blood flow change index was calculated for 24 hours.
• the blood flow change index was calculated to evaluate the effect of hesperetin on the blood flow in the back of the rabbit. Higher means that the effect of promoting microcirculation is better.
• the experimental results were statistically analyzed with SPSS 11.5 software. The measurement results were evaluated by t test. P ⁇ 0.01 can be considered statistically significant. In the results of Table 1, all time points at which P ⁇ 0.1 were present in the 24-hour test.
• METHODS This study used an 8-week two-use contrast test on both sides of the eye.
• 50 moderate-to-severe black-spotted volunteers were recruited, ensuring that the effective number of each paired comparison group was 15.
• the subjects were randomly assigned and left/right balanced, with a composition containing hesperetin on one side and a composition containing no hesperetin on the other side for 8 weeks.
• the efficacy of the black eyelid removal effect was evaluated at 0 weeks (before treatment), 2 weeks, 4 weeks, 6 weeks, and 8 weeks.
• Efficacy evaluation method The eye image of the subject was taken as a reference material for 0 days, and the image was taken for 2, 4, 6 and 8 weeks.
• the photoshop software Lab system was used for colorimetric analysis calculation, and the L value was used to indicate the whiteness of the eye skin. The higher the L value, the whiter the skin, compared with the baseline data, the SPSS statistical results were used to evaluate the product. Efficacy, P ⁇ 0.1 can be considered statistically significant.
• Pairwise comparison 1 Composition 1 (basic formula) versus composition 2 (basic formula + 0.5% hesperetin);
• Pairwise comparison 2 Composition 1 (basic formula) versus composition 3 (basic formula + 2% orange peel);
• Pairwise comparison 3 Composition 1 (basic formula) vs. composition 4 (basic formula + 10% hesperetin extract).
• Base formula +0. 5% hesperetin provided a significantly greater improvement than the base formula at 6 weeks of use (P ⁇ 0.05).
• the basic formula of the active ingredient is also changed. Deducting this change will help to improve the accuracy of the test.
• Reasons for this change in the base formula may include, but are not limited to, non-objective factors such as the stimulating effects of the base formula itself, the heat and cold stimuli, mood, and the brightness of the shooting environment. These factors may cause the L value to change, thereby reducing the objectivity of the test results, so the experimental conditions need to be strictly controlled during the experiment. Setting the left and right eye self-controls in the experimental method can eliminate or balance the influence of irrelevant variables during the experiment to the greatest extent. Therefore, the difference between the experimental group and the control group can be regarded as the effect from the experimental variables.
• the test results show that the L value on the side of the smear base formulation has different paths in different test times.
• the increase of the degree indicates that the non-objective factors have a certain influence on the L value under the experimental conditions, and the L value of the side to which the hesperidin is added is increased to a greater extent, which is significant compared with the former, and indicates that the significant Sex is caused by the effect of hesperetin.
• Table 4B compares the average improvement of 2 pairs of black eyelids in pairs
• Base Formula + 10% Hesperetin Extract provides significantly greater improvement over the base formulation at 2 weeks of use (P ⁇ 0.05).
• the results of the pairwise comparisons indicate that after the addition of hesperetin to the composition, Compared with the composition without the addition of hesperetin, it has a significant effect of improving the black eyelids.
• hesperetin can be used to improve skin microcirculation, especially skin microcirculation around the eyes, especially in cosmetic skin care products used to remove black eyelids.
• compositions of the present invention which can be processed in a conventional manner. They are suitable for cosmetic skin care applications, in particular the compositions are suitable for use in removing dark eyelids to improve the appearance and feel of the eye skin.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Natural Medicines & Medicinal Plants (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Botany (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Alternative & Traditional Medicine (AREA)
• Birds (AREA)
• Medical Informatics (AREA)
• Dermatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Ophthalmology & Optometry (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Cosmetics (AREA)
• Medicines Containing Plant Substances (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=45048905

Family Applications (1)

Country Status (6)

Families Citing this family (5)

Citations (2)

Family Cites Families (11)

• 2010
  • 2010-07-20 CN CN201010231389.2A patent/CN102266320B/zh active Active
• 2011
  • 2011-06-15 WO PCT/CN2011/075765 patent/WO2012010022A1/zh not_active Ceased
  • 2011-06-15 EP EP11809210.5A patent/EP2596787B1/en active Active
  • 2011-06-15 JP JP2013519943A patent/JP5871921B2/ja active Active
  • 2011-06-15 US US13/810,828 patent/US9351952B2/en active Active
  • 2011-06-15 KR KR1020137003693A patent/KR101817514B1/ko active Active

Patent Citations (2)

Also Published As

Similar Documents

Legal Events